Abstract
In the last decade radiotracers have been gradually growing in importance as aids for the development of new drugs. This development has been most pronounced for Psychiatric and Neurologic drugs [1, 2], but has more recently been adapted to the development of drugs against cancer. In this mini-review, we describe how advances in molecular imaging of cancer are likely to lead to advances in development and improved application of anti-cancer drugs [3]. We will focus on 4 aspects of use of radiotracers: 1) for treatment response assessment; 2) for the study of kinetics and pharmacology of novel drugs, including bioavailability and local tumor concentration; 3) the identification of the biologic target at the cellular level; 4) the combination of nanocarriers and radioisotopes to improve biodistribution.
Keywords: Drug Development, radiotracers, molecular imaging, anti-cancer drugs, Cancer Biology
Current Pharmaceutical Design
Title: Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Volume: 15 Issue: 9
Author(s): Steven M. Larson
Affiliation:
Keywords: Drug Development, radiotracers, molecular imaging, anti-cancer drugs, Cancer Biology
Abstract: In the last decade radiotracers have been gradually growing in importance as aids for the development of new drugs. This development has been most pronounced for Psychiatric and Neurologic drugs [1, 2], but has more recently been adapted to the development of drugs against cancer. In this mini-review, we describe how advances in molecular imaging of cancer are likely to lead to advances in development and improved application of anti-cancer drugs [3]. We will focus on 4 aspects of use of radiotracers: 1) for treatment response assessment; 2) for the study of kinetics and pharmacology of novel drugs, including bioavailability and local tumor concentration; 3) the identification of the biologic target at the cellular level; 4) the combination of nanocarriers and radioisotopes to improve biodistribution.
Export Options
About this article
Cite this article as:
Larson M. Steven, Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787581959
DOI https://dx.doi.org/10.2174/138161209787581959 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients
Reviews on Recent Clinical Trials Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Prophylaxis of Cancer
Current Cancer Therapy Reviews Novel Oral Anticoagulants in the Management of Polycythemia Vera and Essential Thrombocythemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain
Current Neuropharmacology Liver and Pancreatic Disease in Cystic Fibrosis: Clinics and Drug Therapy
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Medicinal and Cosmetic Potentials of Sophorolipids
Mini-Reviews in Medicinal Chemistry Molecular Docking for Identification of Potential Targets for Drug Repurposing
Current Topics in Medicinal Chemistry Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Buccoadhesive Dosage Form Containing Antifungal Agent for Treating Oropharyngeal Candidiasis: A Review
Current Drug Therapy Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design The Position of Endoscopic Procedures in the Treatment of Obesity
Current Clinical Pharmacology Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Current Drug Targets